This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, W.-J. Articles by Bae, S.-C. Search for Related Content PubMed PubMed Citation Articles by Kim, W.-J. Articles by Bae, S.-C.

RUNX3 Inactivation by Point Mutations and Aberrant DNA Methylation in Bladder Tumors

Departments of ¹ Urology and ² Biochemistry, College of Medicine, Institute for Tumor Research, Chungbuk National University, Cheongju, South Korea; ³ Department of Urology, Yanbian University College of Medicine, Yanji, China; and ⁴ Institute of Molecular and Cell Biology, Singapore, Singapore

Requests for reprints: Suk-Chul Bae, Institute for Tumor Research, Chungbuk National University, Cheongju 361-763, South Korea. Phone: 82-43-261-2842; Fax: 82-43-274-8705; E-mail: scbae{at}chungbuk.ac.kr or Wum-Jae Kim, Department of Urology, Chungbuk National University, Cheongju 361-763, South Korea. Phone: 82-43-269-6371; Fax: 82-43-271-7716; E-mail: wjkim{at}chungbuk.ac.kr.

RUNX3 is inactivated at high frequency in many tumors. However, in most cases, inactivation is caused by silencing of the gene due to promoter hypermethylation. Because epigenetic silencing is known to affect many major tumor suppressor genes in cancer cells, it is not clear whether RUNX3 is primarily responsible for the induction of carcinogenesis in these cases, except for the gastric cancer cases that we reported previously. We investigated genetic and epigenetic alterations of RUNX3 in 124 bladder tumor cases and seven bladder tumor–derived cell lines. Here we show that RUNX3 is inactivated by aberrant DNA methylation in 73% (90 of 124) of primary bladder tumor specimens and 86% (six of seven) of bladder tumor cell lines. In contrast, the promoter regions of 20 normal bladder mucosae were unmethylated. Importantly, one patient bore missense mutations, each of which resulted in amino acid substitutions in the highly conserved Runt domain. The mutations abolished the DNA-binding ability of RUNX3. A second patient had a single nucleotide deletion within the Runt domain coding region that resulted in truncation of the protein. RUNX3 methylation was a significant risk factor for bladder tumor development, superficial bladder tumor recurrence, and subsequent tumor progression. These results strongly suggest that inactivation of RUNX3 may contribute to bladder tumor development and that promoter methylation and silencing of RUNX3 could be useful prognostic markers for both bladder tumor recurrence and progression.

This article has been cited by other articles:

				Z. Zhang, S. Wang, M. Wang, N. Tong, G. Fu, and Z. Zhang Genetic variants in RUNX3 and risk of bladder cancer: a haplotype-based analysis Carcinogenesis, October 1, 2008; 29(10): 1973 - 1978. [Abstract] [Full Text] [PDF]

				E. M. Wolff, G. Liang, C. C. Cortez, Y. C. Tsai, J. E. Castelao, V. K. Cortessis, D. D. Tsao-Wei, S. Groshen, and P. A. Jones RUNX3 Methylation Reveals that Bladder Tumors Are Older in Patients with a History of Smoking Cancer Res., August 1, 2008; 68(15): 6208 - 6214. [Abstract] [Full Text] [PDF]

				Q. C. Lau, E. Raja, M. Salto-Tellez, Q. Liu, K. Ito, M. Inoue, T. C. Putti, M. Loh, T. K. Ko, C. Huang, et al. RUNX3 Is Frequently Inactivated by Dual Mechanisms of Protein Mislocalization and Promoter Hypermethylation in Breast Cancer. Cancer Res., July 1, 2006; 66(13): 6512 - 6520. [Abstract] [Full Text] [PDF]